HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Vladimir Tolmachev Selected Research

seribantumab

9/2021HER3 PET Imaging: 68Ga-Labeled Affibody Molecules Provide Superior HER3 Contrast to 89Zr-Labeled Antibody and Antibody-Fragment-Based Tracers.
6/2020Evaluating the Therapeutic Efficacy of Mono- and Bivalent Affibody-Based Fusion Proteins Targeting HER3 in a Pancreatic Cancer Xenograft Model.
1/2018Evaluation of the Therapeutic Potential of a HER3-Binding Affibody Construct TAM-HER3 in Comparison with a Monoclonal Antibody, Seribantumab.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Vladimir Tolmachev Research Topics

Disease

168Neoplasms (Cancer)
05/2022 - 01/2002
26Prostatic Neoplasms (Prostate Cancer)
05/2022 - 04/2011
25Breast Neoplasms (Breast Cancer)
01/2022 - 08/2004
16Neoplasm Metastasis (Metastasis)
05/2022 - 11/2004
14Carcinoma (Carcinomatosis)
05/2020 - 11/2004
6Ovarian Neoplasms (Ovarian Cancer)
05/2022 - 06/2005
6Squamous Cell Carcinoma of Head and Neck
12/2019 - 11/2004
5Glioma (Gliomas)
01/2018 - 05/2003
5Glioblastoma (Glioblastoma Multiforme)
01/2018 - 08/2003
5Colorectal Neoplasms (Colorectal Cancer)
01/2014 - 10/2005
5Neoplasm Micrometastasis
09/2009 - 02/2002
3Renal Cell Carcinoma (Grawitz Tumor)
10/2019 - 02/2015
2Lymphoma (Lymphomas)
06/2022 - 05/2020
2Disease Progression
01/2021 - 06/2019
2Adenocarcinoma
02/2020 - 05/2012
2Squamous Cell Carcinoma (Epidermoid Carcinoma)
02/2016 - 01/2011
1Osteosarcoma (Osteogenic Sarcoma)
05/2022
1Triple Negative Breast Neoplasms
10/2020
1Pancreatic Neoplasms (Pancreatic Cancer)
06/2020
1Hypoxia (Hypoxemia)
12/2019

Drug/Important Bio-Agent (IBA)

68Radioisotopes (Radionuclides)IBA
05/2022 - 02/2002
35ErbB Receptors (EGF Receptor)IBA
01/2022 - 08/2004
25Proteins (Proteins, Gene)FDA Link
11/2021 - 02/2004
251,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidIBA
10/2020 - 02/2007
18Monoclonal AntibodiesIBA
01/2022 - 11/2004
17Trastuzumab (Herceptin)FDA Link
01/2022 - 06/2005
16Bombesin Receptors (Bombesin Receptor)IBA
11/2021 - 01/2013
16Chelating AgentsIBA
03/2020 - 11/2006
13human ERBB2 proteinIBA
01/2022 - 06/2005
131,4,7- triazacyclononane- N,N',N''- triacetic acid (NOTA)IBA
11/2021 - 05/2011
12AntigensIBA
07/2020 - 10/2005
11Epidermal Growth Factor (EGF)IBA
01/2021 - 05/2003
10Pharmaceutical PreparationsIBA
02/2022 - 10/2007
101- (1,3- carboxypropyl)- 4,7- carboxymethyl- 1,4,7- triazacyclononaneIBA
12/2020 - 03/2012
8Designed Ankyrin Repeat ProteinsIBA
05/2022 - 01/2018
8AntibodiesIBA
06/2020 - 08/2003
7BombesinIBA
01/2020 - 01/2013
7Pentetic Acid (DTPA)FDA LinkGeneric
12/2019 - 08/2003
7Cys-ZHER2-342 affibodyIBA
01/2018 - 02/2007
6Epithelial Cell Adhesion MoleculeIBA
05/2022 - 02/2020
6AlbuminsIBA
02/2022 - 01/2018
6Peptides (Polypeptides)IBA
10/2020 - 01/2002
6ABY-025IBA
03/2020 - 04/2010
6AndrogensIBA
07/2014 - 04/2011
5Indium-111IBA
07/2021 - 04/2007
5Tyrosine Kinase InhibitorsIBA
01/2021 - 11/2014
5LigandsIBA
06/2020 - 04/2006
4Immunoconjugates (Immunoconjugate)IBA
05/2022 - 11/2006
3seribantumabIBA
09/2021 - 01/2018
3Carbonic Anhydrase IXIBA
12/2019 - 11/2016
3Hormones (Hormone)IBA
01/2019 - 04/2011
3Cetuximab (Erbitux)FDA Link
01/2019 - 01/2011
3Biomarkers (Surrogate Marker)IBA
01/2018 - 07/2010
3Peptide Nucleic AcidsIBA
01/2018 - 01/2016
3Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
12/2017 - 03/2009
3Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
04/2016 - 01/2007
3Cysteine (L-Cysteine)FDA Link
04/2015 - 03/2007
2Glucose (Dextrose)FDA LinkGeneric
06/2022 - 02/2016
2EpitopesIBA
11/2021 - 05/2012
2Aligeron (AS 2)IBA
01/2021 - 06/2010
268Ga-ABY-025IBA
03/2020 - 01/2016
2EnzymesIBA
01/2020 - 11/2016
2G250 monoclonal antibodyIBA
12/2019 - 02/2015
2CobaltIBA
11/2019 - 01/2017
2Immunoglobulin FragmentsIBA
10/2019 - 02/2016
2Immunoglobulins (Immunoglobulin)IBA
01/2018 - 01/2016
2pertuzumabIBA
01/2018 - 01/2007
2Technetium (Technetium 99m)IBA
01/2018 - 03/2006
2CD44v6 antigenIBA
02/2016 - 01/2010
2Oncogene Proteins (Oncogene Protein)IBA
10/2015 - 06/2006
2IndiumIBA
06/2014 - 11/2007
2IodineIBA
06/2014 - 03/2006
2IsotopesIBA
07/2013 - 11/2004
2RadiopharmaceuticalsIBA
03/2011 - 03/2007
2DABIIBA
01/2010 - 11/2004
2dodecaborateIBA
01/2010 - 11/2004
2benzyl-DTPAIBA
09/2007 - 08/2003
2N- (2- amino- 3- (para- isothiocyanatophenyl)propyl)cyclohexane- 1,2- diamine- N,N,N',N',N'- pentaacetic acidIBA
03/2007 - 11/2006
2Benzoates (Benzoate)IBA
07/2006 - 11/2004
1Alkaline PhosphataseIBA
05/2022
1OsteopontinIBA
05/2022
1ExotoxinsIBA
05/2022
1Gallium-66IBA
11/2021
1glycylhistidineIBA
01/2021
1Copper-64IBA
12/2020
1Cobalt-55IBA
12/2020
1Human Serum AlbuminFDA LinkGeneric
10/2020
1Blood Proteins (Serum Proteins)IBA
01/2020
1phosphoramidonIBA
12/2019
1pimonidazoleIBA
12/2019
1GlutamatesIBA
08/2019

Therapy/Procedure

86Therapeutics
05/2022 - 02/2002
7Radioimmunotherapy
08/2015 - 10/2005
7Gamma Cameras (Gamma Camera)
11/2014 - 04/2006
3Radiotherapy
12/2019 - 01/2007
2Investigational Therapies (Experimental Therapy)
12/2020 - 01/2007
2Precision Medicine
07/2019 - 10/2015
2Immunotherapy
01/2018 - 01/2014
2Intravenous Injections
05/2014 - 05/2012
1Cyclotrons
11/2021